ClinicalTrials.gg
TerminatedNCT01855685CGDUpdated Apr 13, 2026

Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)

A Phase 1/2 interventional study of X vivo gene therapy in X-Linked Chronic Granulomatous Disease, sponsored by Genethon. Terminated at 2 sites in United Kingdom. Open to male participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Genethon · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Last patient withdrawed from the study.
Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
6 Months and older
Sex
Male
01

Study summary

X-linked chronic granulomatous disease (X-CGD) is a rare genetic disorder, which affects boys. It is caused by an error in a gene that makes part of the immune system. The basic defect lies in specialised white blood cells called phagocytic cells (or phagocytes), which are responsible for protection against infection by destroying invading bacteria and fungi. They do this by pouring large amounts of substances similar to bleach onto these organisms. In CGD, there is a defect in the system that makes the bleach, called the NADPH-oxidase. In X-CGD (which accounts for two thirds of patients), the defect lies in a gene which makes up a critical part of the NADPH-oxidase (known as gp91-phox), and the cells cannot make bleach-like substances. Therefore they kill bacteria and fungi poorly, and the patients suffer from severe and recurrent infections. This also results in inflammation which can damage parts of the body such as the lung and gut.

In many cases, patients can be adequately protected from infection by constant intake of antibiotics. However, in others, severe life-threatening infections break through. In some cases, inflammation in the bowel or urinary systems results in blockages which cannot be treated with antibiotics, and which may require the use of other drugs such as steroids. Development of curative treatments for CGD is therefore of great importance.

02

Conditions studied

  • X-Linked Chronic Granulomatous Disease

Keywords

  • XCGD, lentivirus, cellular therapy
03

In context

Granulomatous Disease, Chronic

79 studies on the registry are indexed under Granulomatous Disease, Chronic; 17 are open to participants now.

This study's enrollment of 3 is below the median of 12 across 57 interventional studies indexed under Granulomatous Disease, Chronic.

Browse Granulomatous Disease, Chronic studies →

Lead sponsor

Genethon is the lead sponsor of 15 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male X-CGD patients
  • Molecular diagnosis confirmed by DNA sequencing
  • At least one prior ongoing or resistant severe infection and/or inflammatory complications requiring hospitalisation despite conventional therapy
  • No HLA-matched donor available after 3 months search unless the risk of waiting for a potential match or for performing an transplant is considered unacceptable by the investigator

Exclusion criteria

Exclusion Criteria:

  • for leukapheresis
  • Contraindication for administration of conditioning medication
  • Administration of gammainterferon within 30 days before the infusion of transduced autologous CD34+ cells
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Open label

    X vivo gene therapy

    Genetic: X vivo gene therapy

Interventions

  • GeneticX vivo gene therapy

    Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene

06

What researchers measure

Primary outcomes

  1. Safety of the procedure as measured by the incidence of adverse events

    Time frame: 24 months

  2. Restoration and stability over time of the NADPH functioning granulocytes assessed by a DHR test

    Time frame: 12 months

Secondary outcomes

  1. Normalisation of nutritional status, growth, development, severe infection and/or inflammatory complication which recommended patient's inclusion

    Time frame: 24 months

  2. Percentage of transduced CD34+ haematopoietic cells infused and of blood cells over time

    Time frame: 24 months

  3. Immunological reconstitution

    Time frame: 24 months

07

Study locations

2 sites
  • University College London Hospital (UCLH)
    London, NW1 2PG, United Kingdom
  • Great Ormond Street Hospital NHS Foundation Trust
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2013 to primary completion in Jun 2021, 95 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2013
First posted
May 16, 2013
StartActual
Jun 24, 2013
Primary completionActual
Jun 4, 2021
CompletionActual
Oct 17, 2025
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01855685
Lead sponsor
Genethon
Responsible party
Sponsor
First posted
May 16, 2013
Start date
Jun 24, 2013
Primary completion
Jun 4, 2021
Completion
Oct 17, 2025
Last update
Apr 13, 2026

Study contacts

Adrian Thrasher, MD, PHD
principal investigator · Great Ormond Street Hospital NHS Foundation Trust - London - UK
Janine Reichenbach, MD
principal investigator · University Children's Hospital Zürich - Switzerland
Hubert Serve, MD, PHD
principal investigator · Department of Hematology/Oncology, University Hospital Frankfurt and Institute for Biomedical Research, Georg-Speyer-Haus, Frankfurt - Germany
Emma Morris, MD, PHD
principal investigator · Royal Free Hospital / University College London Hospital (UCLH)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion